Active Stocks: Affimed Therapeutics, Rewalk Robotics, Amarin Corporation, Cannabis Science, Oxygen Biotherapeutics
By Marilyn Mullen   
Friday, 12 September 2014 14:09

U.S. stocks slid sharply on Friday, with the Dow industrials on track to snap a five-week stretch of weekly gains, as investors eyed a measure of retail sales and looked ahead to a Federal Reserve meeting next week.

The Dow Jones Industrial Average shed 95 points, or 0.6%, to 16954 in early-afternoon trading. On the week, the blue-chip benchmark was off 1.1%. The S&P 500 index lost 14 points, or 0.7%, to 1983. The Nasdaq Composite Index fell 24 points, or 0.6%, to 4563.

 

Investors didn’t show much enthusiasm for Affimed Therapeutics BV (NASDAQ:AFMD) in its debut today. Shares are down 9% from the $7 offer price on turnover of 2.6M.The German clinical-state biopharmaceutical firm focuses on cancer immunotherapies. Its lead product is is the TandAb AFM13 for Hodgkin Lymphoma. It is currently in Phase 2 clinicals.

Investors are showing Rewalk Robotics Ltd. (NASDAQ:RWLK) a lot of love in its debut today. Shares are up 123% from the $12 offer price on turnover of almost 10M. The company makes a robotic exoskeleton that enables a paraplegic to stand and walk. The firm's founder, Dr. Amit Goffer, knows how profound an innovation this is. He is a quadriplegic.

Amarin Corporation plc (ADR)(NASDAQ:AMRN) slumped 18% on huge volume in following company's announcement that the FDA denied its appeal on the regulator's rescission of the ANCHOR SPA.

Cannabis Science Inc. (OTCMKTS:CBIS) forms a joint venture with Unistraw Holdings Pte. Ltd., to develop cannabinoid-based foods, nutraceuticals and medical products. CBIS will own 50.5% of the JV and Unistraw will own 49.5%.

Oxygen Biotherapeutics, Inc.(NASDAQ:OXBT) stops its Phase 2b clinical trial evaluating the safety and tolerability of Oxycyte, a proprietary perfluorocarbon therapeutic oxygen carrier, in patients with severe non-penetrating traumatic brain injury due to the difficulty in enrolling patients. Completing the trial in a reasonable amount of time is no longer feasible.




"Featured Content" profiles are meant to provide awareness of these companies to investors in the small-cap and growth equity community and should not in any way come across as a recommendation to buy, sell or hold these securities. BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and investor relation services from various entities and firms. Full disclosures should be read in the 'About Us Section'.

Add this page to your favorite Social Bookmarking websites
Digg! Reddit! Del.icio.us! Mixx! Google! Live! Facebook! Technorati! StumbleUpon! MySpace! Yahoo!

blog comments powered by Disqus
 

Newsletter